In the ex vivo PDE experiment, the combination of riluzole and fulvestrant was highly effective and more robust than either agent alone, with 80% (4/5) of primary tumor explants showing significant growth inhibition by the combination as measured by a reduction in PCNA (Fig. 7). This evidence concerns the gene ALDH7A1 and neoplasm.